8-K current report · filed Nov 3, 2026

RHYTHM PHARMACEUTICALS, INC. (RYTM) 8-K Current Report: November 3, 2026

Item 2.02Item EX-99.1Item EX-99.2RYTM overview

Short answer

RHYTHM PHARMACEUTICALS, INC. (RYTM) filed an 8-K current report with the SEC on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Third-quarter fiscal 2026 results announced for the period ended September 30, 2026.

RHYTHM PHARMACEUTICALS, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Third-quarter fiscal 2026 results announced for the period ended September 30, 2026
  • Full financial results available in furnished Exhibit 99.1, the company’s accompanying press release

Item EX-99.1 · Exhibit EX-99.1

  • Q3 product revenue $92.1M, up 29% sequentially and 80% year over year, signaling accelerating IMCIVREE commercialization
  • Acquired HO launch generated 700+ U.S. patient start forms from 500+ prescribers by September 30
  • U.S. revenue $67.5M, up 32% sequentially, while ex-U.S. revenue reached $24.7M, up 22%
  • Bivamelagon royalty amendment requires $350M over four years, reducing future MC4R portfolio royalties to 1%
  • New five-year term loan provides up to $750M, including a $250M initial draw, strengthening funding for pivotal development and launches

Item EX-99.2 · Exhibit EX-99.2

  • Q3 2026 net product revenue $92.1M, up from $51.3M, with 73% generated in the U.S.
  • IMCIVREE revenue increased 29% QoQ, supported by U.S. acquired hypothalamic obesity launch and 20% growth in reimbursed patients
  • Bivamelagon advances to two global Phase 3 trials, targeting acquired hypothalamic obesity and Prader-Willi syndrome
  • LG Chem royalty reduced to 1% from low-to-mid-single digits, but amended terms add $350M payments and a potential $200M commercial milestone
  • $750M term loan facility secured at SOFR plus 4.60%, with $250M initially drawn and cash resources of $320.9M at September 30, 2026

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other RHYTHM PHARMACEUTICALS, INC. 8-K filings

Get the next RYTM 8-K as it lands

Follow RYTM for push alerts, or ask the research agent what this filing means.